Overview

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Status:
RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

mirikizumab
Tirzepatide